Salivary Gland Adenocarcinoma
Associated Genetic Biomarkers
NCI Definition: An adenocarcinoma arising from the salivary gland. It includes the salivary gland polymorphous low grade adenocarcinoma, salivary gland oncocytic carcinoma, salivary gland mucinous adenocarcinoma, salivary gland low grade cribriform cystadenocarcinoma, salivary gland cystadenocarcinoma, salivary gland basal cell adenocarcinoma, salivary gland acinic cell carcinoma, salivary duct carcinoma, and salivary gland adenocarcinoma not otherwise specified. 
Salivary gland adenocarcinomas most frequently harbor alterations in TP53, ERBB2, CDKN2A, PIK3CA, and ETV6 .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, PIK3CA Mutation, and ERBB2 Amplification are the most common alterations in salivary gland adenocarcinoma .
There are 3 clinical trials for salivary gland adenocarcinoma, of which 3 are open and 0 are completed or closed. Of the trials that contain salivary gland adenocarcinoma as an inclusion criterion, 3 are phase 2 (3 open).
ERBB2 and HER2 are the most frequent gene inclusion criteria for salivary gland adenocarcinoma clinical trials .
Nanoparticle-based paclitaxel suspension, cisplatin, and lenvatinib are the most common interventions in salivary gland adenocarcinoma clinical trials.
Significant Genes in Salivary Gland Adenocarcinoma
ERBB2 is altered in 15.15% of salivary gland adenocarcinoma patients .
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for salivary gland adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary gland adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.